Page 2 - Controlled Equity News Today

GUGGENHEIM STRATEGIC OPPORTUNITIES FUND COMMON SHARES THIRD AMENDMENT TO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT ... | April 11, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13... | April 7, 2023

Item 1.01. Entry into a Material Definitive Agreement. On April 6, 2023, Altus Power, Inc, a Delaware corporation , entered into a Controlled Equity OfferingSM Sales Agreement ... | April 6, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ... | March 31, 2023

* Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 * European Commission granted orphan... | March 29, 2023

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome; topline results expected first-half 2024 European Commission granted... | March 28, 2023

Investegate announcements from Nyxoah, Nyxoah Raises $3 Million from an At-the-Market Equity Offering

INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Raises $3 Million from an At-the-Market Equity Offering  Mont-Saint-Guibert, Belgium – March 27, 2023,...

Toronto, Ontario--(Newsfile Corp. - January 6, 2023) - Seabridge Gold Inc. (TSX: SEA) (NYSE: SA) (the "Company" or "Seabridge") announces that it has entered into a Controlled Equity OfferingSM Sales

14.11.2022 - Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into ...